Constance Cirrincione

16.4k total citations · 7 hit papers
81 papers, 9.8k citations indexed

About

Constance Cirrincione is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Constance Cirrincione has authored 81 papers receiving a total of 9.8k indexed citations (citations by other indexed papers that have themselves been cited), including 62 papers in Oncology, 37 papers in Cancer Research and 20 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Constance Cirrincione's work include Breast Cancer Treatment Studies (37 papers), Cancer Treatment and Pharmacology (31 papers) and HER2/EGFR in Cancer Research (23 papers). Constance Cirrincione is often cited by papers focused on Breast Cancer Treatment Studies (37 papers), Cancer Treatment and Pharmacology (31 papers) and HER2/EGFR in Cancer Research (23 papers). Constance Cirrincione collaborates with scholars based in United States, France and Canada. Constance Cirrincione's co-authors include Donald A. Berry, Hyman B. Muss, Eric P. Winer, Clifford A. Hudis, Larry Norton, I. Craig Henderson, William C. Wood, Daniel R. Budman, Beryl McCormick and Kevin S. Hughes and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.

In The Last Decade

Constance Cirrincione

80 papers receiving 9.4k citations

Hit Papers

Improved Outcomes From Adding Sequential Paclitaxel but N... 1994 2026 2004 2015 2003 2013 1994 2004 2013 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer
    2003 921 citations I. Craig Henderson, Donald A. Berry et al. Journal of Clinical Oncology profile →
  2. Lumpectomy Plus Tamoxifen With or Without Irradiation in Women Age 70 Years or Older With Early Breast Cancer: Long-Term Follow-Up of CALGB 9343
    2013 826 citations Jennifer R. Bellon, Constance Cirrincione et al. Journal of Clinical Oncology profile →
  3. c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer
    1994 779 citations Hyman B. Muss, Ann D. Thor et al. New England Journal of Medicine profile →
  4. Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer
    2004 733 citations Donald A. Berry, Constance Cirrincione et al. New England Journal of Medicine profile →
  5. Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy
    2013 718 citations Elizabeth Smith, Herbert Pang et al. JAMA profile →
  6. Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
    2014 650 citations William M. Sikov, Donald A. Berry et al. Journal of Clinical Oncology profile →
  7. Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer
    2006 518 citations Donald A. Berry, Constance Cirrincione et al. JAMA profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Constance Cirrincione United States 38 6.8k 4.7k 1.6k 1.6k 1.3k 81 9.8k
John H. Glick United States 43 5.8k 0.9× 3.1k 0.7× 1.8k 1.1× 3.1k 2.0× 1.5k 1.1× 113 9.7k
Frankie A. Holmes United States 42 6.7k 1.0× 3.1k 0.7× 1.3k 0.8× 939 0.6× 1.6k 1.2× 135 9.0k
Christoph Thomssen Germany 53 4.9k 0.7× 4.5k 1.0× 1.2k 0.8× 944 0.6× 2.2k 1.7× 281 8.4k
Semiglazov Vf Russia 46 8.5k 1.2× 5.6k 1.2× 2.1k 1.3× 1.5k 0.9× 2.1k 1.6× 239 11.9k
Christian Jackisch Germany 52 8.5k 1.2× 6.2k 1.3× 1.8k 1.2× 2.2k 1.4× 1.8k 1.4× 356 12.6k
Nicholas J. Robert United States 44 6.7k 1.0× 4.1k 0.9× 2.0k 1.2× 926 0.6× 2.0k 1.6× 181 10.0k
Bernard Asselain France 59 5.2k 0.8× 4.4k 0.9× 2.1k 1.3× 2.6k 1.7× 2.0k 1.6× 323 11.0k
Michael Andersson Denmark 37 3.2k 0.5× 2.2k 0.5× 1.7k 1.1× 1.6k 1.0× 1000 0.8× 123 7.6k
Henri Roché France 44 6.4k 0.9× 3.3k 0.7× 1.8k 1.1× 725 0.5× 2.1k 1.6× 213 9.0k
Jens‐Uwe Blohmer Germany 41 6.2k 0.9× 6.3k 1.4× 1.4k 0.9× 2.5k 1.6× 1.1k 0.8× 322 10.0k

Countries citing papers authored by Constance Cirrincione

Since Specialization
Citations

This map shows the geographic impact of Constance Cirrincione's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Constance Cirrincione with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Constance Cirrincione more than expected).

Fields of papers citing papers by Constance Cirrincione

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Constance Cirrincione. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Constance Cirrincione. The network helps show where Constance Cirrincione may publish in the future.

Co-authorship network of co-authors of Constance Cirrincione

This figure shows the co-authorship network connecting the top 25 collaborators of Constance Cirrincione. A scholar is included among the top collaborators of Constance Cirrincione based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Constance Cirrincione. Constance Cirrincione is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cardona, Diana M., Anthony D. Sung, Martin Poleski, et al.. (2018). Use of the National Institutes of Health Consensus Guidelines Improves the Diagnostic Sensitivity of Gastrointestinal Graft-Versus-Host Disease. Archives of Pathology & Laboratory Medicine. 142(9). 1098–1105. 4 indexed citations
2.
Sung, Anthony D., Syed Adeel Hassan, Diana M. Cardona, et al.. (2017). Late Gastrointestinal Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Adults. Biology of Blood and Marrow Transplantation. 24(4). 734–740. 7 indexed citations
3.
Golshan, Mehra, Constance Cirrincione, William M. Sikov, et al.. (2016). Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance). Breast Cancer Research and Treatment. 160(2). 297–304. 60 indexed citations
4.
Carey, Lisa A., Donald A. Berry, Constance Cirrincione, et al.. (2015). Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib. Journal of Clinical Oncology. 34(6). 542–549. 263 indexed citations
5.
Sikov, William M., Donald A. Berry, Charles M. Perou, et al.. (2014). Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance). Journal of Clinical Oncology. 33(1). 13–21. 650 indexed citations breakdown →
6.
Smith, Elizabeth, Herbert Pang, Constance Cirrincione, et al.. (2013). Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy. JAMA. 309(13). 1359–1359. 718 indexed citations breakdown →
7.
Hamilton, Erika, Jeffrey Peppercorn, P. Kelly Marcom, et al.. (2013). Clinical impact of febrile neutropenia (FN) increase among patients receiving adjuvant docetaxel/cyclophosphamide (TC) chemotherapy compared to TC plus pegfilgrastim for breast cancer.. Journal of Clinical Oncology. 31(15_suppl). 1076–1076. 4 indexed citations
8.
Smith, Elizabeth, Herbert Pang, Constance Cirrincione, et al.. (2012). CALGB 170601: A phase III double blind trial of duloxetine to treat painful chemotherapy-induced peripheral neuropathy (CIPN).. Journal of Clinical Oncology. 30(15_suppl). CRA9013–CRA9013. 10 indexed citations
9.
Marks, Lawrence B., Constance Cirrincione, Thomas J. FitzGerald, et al.. (2009). Impact of High-Dose Chemotherapy on the Ability to Deliver Subsequent Local–Regional Radiotherapy for Breast Cancer: Analysis of Cancer and Leukemia Group B Protocol 9082. International Journal of Radiation Oncology*Biology*Physics. 76(5). 1305–1313. 18 indexed citations
10.
11.
Berry, Donald A., Constance Cirrincione, I. Craig Henderson, et al.. (2006). Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer. Obstetrical & Gynecological Survey. 61(9). 584–585. 24 indexed citations
12.
Berry, Donald A., Constance Cirrincione, I. Craig Henderson, et al.. (2006). Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer. JAMA. 295(14). 1658–1658. 518 indexed citations breakdown →
13.
Hayes, Daniel F., Hideko Yamauchi, Gloria Broadwater, et al.. (2001). Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.. PubMed. 7(9). 2703–11. 75 indexed citations
14.
Mitchell, Edith, Michael C. Perry, Sharon D. Luikart, et al.. (1996). A phase trial of etoposide and cisplatin in extensive small cell lung cancer: A cancer and Leukemia Group B study. Lung Cancer. 15(2). 215–223. 4 indexed citations
15.
Muscato, Joseph J., Constance Cirrincione, Gerald H. Clamon, et al.. (1995). Etoposide (VP-16) and cisplatin at maximum tolerated dose in non-small cell lung carcinoma: a Cancer and Leukemia Group B study. Lung Cancer. 13(3). 285–294. 9 indexed citations
16.
Muss, Hyman B., Ann D. Thor, Donald A. Berry, et al.. (1994). c-erbB-2 Expression and Response to Adjuvant Therapy in Women with Node-Positive Early Breast Cancer. New England Journal of Medicine. 330(18). 1260–1266. 779 indexed citations breakdown →
17.
Hagen, Neil A., Constance Cirrincione, Howard T. Thaler, & Lisa M. DeAngelis. (1990). The role of radiation therapy following resection of single brain metastasis from melanoma. Neurology. 40(1). 158–158. 128 indexed citations
18.
Recht, Lawrence D., David J. Straus, Constance Cirrincione, Howard T. Thaler, & Jerome B. Posner. (1988). Central nervous system metastases from non-hodgkin's lymphoma: Treatment and prophylaxis. The American Journal of Medicine. 84(3). 425–435. 81 indexed citations
19.
Lieberman, Philip, Daniel A. Filippa, David J. Straus, et al.. (1986). Evaluation of malignant lymphomas using three classifications and the working formulation. The American Journal of Medicine. 81(3). 365–380. 26 indexed citations
20.
Bosl, George J., Nancy L. Geller, Constance Cirrincione, et al.. (1983). Serum tumor markers in patients with metastatic germ cell tumors of the testis. The American Journal of Medicine. 75(1). 29–35. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by John H. Glick Breakdown of academic impact, for papers by Frankie A. Holmes Breakdown of academic impact, for papers by Christoph Thomssen Breakdown of academic impact, for papers by Semiglazov Vf Breakdown of academic impact, for papers by Christian Jackisch Breakdown of academic impact, for papers by Nicholas J. Robert Breakdown of academic impact, for papers by Bernard Asselain Breakdown of academic impact, for papers by Michael Andersson Breakdown of academic impact, for papers by Henri Roché Breakdown of academic impact, for papers by Jens‐Uwe Blohmer
Rankless by CCL
2026